Nobilis Rismavac+CA126 consists of a suspension of living, cultured avian cells containing at least 3.0 log10 pfu Marek's Disease virus (strain CVI 998) and at least 3.0 log10 pfu Turkey Herpes Virus (strain FC 126) per dose. The vaccine contains stabilisers and traces of antibiotics (neomycin and polymyxin or gentamycin, and amphotericin B). Nobilis Rismavac+CA126 is supplied in frozen ampoules held in metal canes stored in a liquid nitrogen canister. Nobilis Diluent CA is supplied for reconstitution of the vaccine prior to use.
Nobilis Rismavac+CA126 is to reduce mortality, clinical signs and lesions after infection with Marek’s disease virus (MDV).
For uses, dosage, contra-indications and warnings, please see data sheet. Use medicine responsibly. Further information is available on request.
Ampoules containing 1,000, 2,000, 4000 or 5000 doses supplied together with Nobilis Diluent CA (Vm 01708/4270). Not all presentations may be marketed.